



GEDEON RICHTER

Celebrating 125 years

Agreement with foundations regarding the dividend payment schedule

Budapest, 29 April 2026 – Gedeon Richter Plc. (“Richter” or the “Company”) hereby announces that, as of today, it has concluded an agreement with three public-interest asset management foundations holding an ownership in the Company regarding the schedule for the payment of dividends due to such foundations in respect of the 2025 financial year, for which the dividend was approved by the General Meeting held on 29 April 2026. Under the agreement, the dividends payable to these foundations will be paid no later than 11 September 2026.

This agreement does not affect other shareholders of the Company.

About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe’s largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women’s Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

For further information:

Investors: Róbert Réthy, CFA
Media: Zsuzsa Beke

+36 20 342 2555
+36 20 916 4507

Chemical Works of Gedeon Richter Plc.

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary

Phone: +36 1 431 4000 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944

EU Community VAT Identification No: HU 10484878 • www.gedeonrichter.com